Table 1 Baseline characteristics of patients
Characteristic | Fluvoxamine (n = 42) | Placebo (n = 43) | P-value | |
|---|---|---|---|---|
Age | 39.8 ± 14 [19–70] | 37.2 ± 14.3 [18–75] | 0.399 | |
Sex | ||||
Women | 20 (47.6%) | 21 (48.8%) | 0.911 | |
Men | 22 (52.4%) | 22 (51.2%) | ||
COVID-19 Vaccination | ||||
AstraZeneca | 13 (31%) | 10 (23.3%) | 0.769 | |
Sinopharm | 28 (66.7%) | 31 (72.1%) | ||
Sputnik | 1 (2.4%) | 1 (2.3%) | ||
Pastocovak | 0 (0%) | 1 (2.3%) | ||
Past medical history | ||||
Hypertension | 2 (4.8%) | 5 (11.6%) | 0.713 | |
Ischemic heart disease | 3 (7.1%) | 2 (4.7%) | 0.676 | |
Diabetes mellitus | 2 (4.8%) | 1 (2.3%) | 0.616 | |